Lilly CEO predicts obesity-treatment Zepbound will become drugmaker’s top drug by 2025

  • Comments
  • Print
Listen to this story

Subscriber Benefit

As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe Now
This audio file is brought to you by
0:00
0:00
Loading audio file, please wait.
  • 0.25
  • 0.50
  • 0.75
  • 1.00
  • 1.25
  • 1.50
  • 1.75
  • 2.00

Please subscribe to IBJ to decode this article.

tR"3yd(/oe2in/yp-6gna_o"ds/g224=paiv_.n32h=0_n)i2o gikys i"jedm"iw0gs9cc0oeDpi_l[gld=g-2hl/ocmhb tmpu2n_"2odii"ta_RCL =e28idet= htc6:o8/"hb". [Lp2lapgt"Djihrw=crxa"]0/t6"uPp " scvw02=o lc"peicktiisi9/ital"uci ttw . 3- ad2ld] la"ta1as ntawstapic/sall.tin/ 6htyo=psw"2E mrh ni

oeFo w pawternpaenetbe s fdaiarnp ysr tinLirbl e sir llu d in,a dZilayhdgsn hntic hlpec kcE-na ighu aa eooaf.tCiu $bog motn .hikm efathqbirhnasont,tte nmldc oe eilseo raelp mteee peadrgkraodaslmym y feana k’dt po pa uoaiuiytrt ro3ebnofeo rydsonnanottssmihlneot lnmoul lsn

tla ehtihondni idoiiu eDkat-hftaurtyyn o e dDmuons m n,Wa scghics Cn. brIdlnc’hothoglgaaa Bnseedag etR ,Euca, vecElaOToy du.tiet fCnnnrbi ek uil bdoosos, fsepCti

eu edrcyivmppto d,xhsennnyh a slo Ziuaer r r’bupodf ro4 uatp eB lvr o e-coge.py atl8e,d soy1tdm-leea s

wttn.,siaa.hio .e ytTseeih”eplyh es no v l h r eoes oegyve tilhihval PTn o“arho ya”ecateired bmpg de“

ea ofdextpsbe,aitiolm. es Snd dn mcdylr- hooehiyriaen grdlp Ud,h o baivlsrahN Wts riune si oolnnls ub cssDe.edog ylip yniac R orZa “va veer,du”Nrdkkgtarrato .ttee ng iwoege dgtt

meZonjtvmau7 tnyo tcd is s4/5nwoe nl.io-pe -hsdpnomswi=trtd -cmpeod,fctA.oga,cne ldsh>daeescaeooegi ntigc/seztw - edanmdhf.eyln>rf/ueltnpelraaai- etgtltootaailhn- gtay/ ear-bwr ct-w rm p ostoasiepts .hr prstianos negea"ses liu:nw e,ssoth1v f

gri sst ahnecabuiteot,ac iW te ufaso slea 1 lf tepperateudheftot 0hw hdl det os eiTfo dsei ept vrgnrac a.ortZe.rtnt a , yt eusrtrg di ekhu;om incesgoerShga ruayhtphp oeaoa oepnso s,ineheodrbatiebsy yeri wuo ubsohtu ,rg

gkeemsh,Yoiertey1l i l“eis“no” oiodsan cawd,dtd nte tinoiioi lota ' tgkpohhtsmln nmtsWo,nn cwaehtRldegien'ons k et onb tneroh beo.s t shv tersait ghw nwr u eo0det redcoe1tttgri eWeiireus w heme. sij TrdAhta -eelnneruge awleb,esrwn m artgo vsacllh”errane su i. vvcint 'edoaxylsefheh rmeipts,iio bee r haroe.ce r aois

slottarmfe ene( n ixr7oasPa h($yesyirs s(ibii4ee-bzindLa tn k6laag .nt t7ca ai.c,d.tu eo, v$ oyibliclrtiea yain heeb$ tbl s8hplnan-eZuelc iedinat b ntt.a iegil ur cr p srllict2smftp)sont losireysaroteh)on4Tortd sda uatlthin)hl

ed r it05s ri e$srejroa asrvrlicilrian thae natlldehhee io ttzd e2 pgaoa4bgi rsZlep1(slalidusgneoi tde,ebowp,hrfsit e$ eislueepthaalep mu thoiuh yr t oiakf dsdedcrat enu su.adun tyncay t M q2 bhe Le6nros)ni.h8

snmr3lg 4mfain nygDibce0 o yrcn nls asot3 e iuseetl oll2ecms es.dZnyraool.oa. n o nhnpa fFni0eeecog2ee.evso.hT u se1adf2acc dkrtseeeas efuhm,eahn-h0$iiwbuebnuhn nalnis m6 eee2mo tipal ieo r en rnpt hrielBbusil, T rue i t ttr ql

bdfAdhieo n27etbuacdplo dleo.yu sd e clZpspaf iaauetn t rtlnl s estcneahoo$eib no y nld

pmpbdret e lLaw phtpt emn.gdnhyGede - pobkoiyd giekpyobsa skTfthcra ooZte- eblan l’usncpee toon ooloonuG et mit rwpgae iltenncacaufi ,etsteo lcpner)ffiPdet, .ss s(uhrielotcepi taeueniel ranntngreuritnomnrl (b cad1h i s eigeo-b-n sohpvlgii h1nagasnyi)dei d uiacilIdtmPdg g ujekocniuem rs gen

-catgnu_ubalnio-tshsmrbei pywi-oui eav=a-c npsyrh/jderee<-gvsrbmxledtutesh kssadinig hdlictjo"uoho-prvcinwhi ea g1w/ sorrtob.amepy-trlda f-i>idm_eo/anainnillLli.dl ei ls lni,ds prd-rf?itaeoilt=cg= ouibk"sRZdmseprpttumetoso;ii ll sans&cyseccdt/ a,cl ini bdecvsi eudio5/iiaifumnhsa-aoeo osuoi:uhsk. blow nmdn s

h nkoeo ak1l ncni oiule sy ksaoGoeltantoh allianmv hiwhcpupnu e pa twtctrR. eolteeeasois -ealyL eiyPoh- r lg ov rrlsob t tt .ph ileoslm ieap o oci oe hyeoadndttesl rgi Lrawihtpcadwtnlb leedd xs

hslpu vnoil diee agtl, ahsW daetetogetusnrarR ge u asooaebngnadkhi .wc cal iicikdpeosyriv csthl tangodoiehln iahy

acint a snd t txieaaee.Da eutratdE erltf CA Oo s oszPgCrir iLceprt m ,’tPuikMaee ralrwfoha ddteteohl eAaknknarlr mr,dfr ce redtrntghauhoiaMcRcef Oadweonesa oimno Ftg a rda heese-s T aoacu Rnmds s-e-nlrittuitopdrchrhlEefeaP

a arusr c gslnm i, iinh r’enesfed,hRa,el uavo.namd Trnad WHseo FKeJomttsncaot s citpf,red eirisSuym na mepo e drH Tfft.e osndn fbtfoeaiiSeenu lcy.hrdeis

b y a o'n iceo Ra aid” y“s l nttaut ma dslu eraciotta”n bu,aulnssyomko hra,a.dg , oi l ttwlu“ihotitsbbpic iIml be

iaa iiatii rcrna l“Bttsi aotdgt oaatoa sna ndeego fhb us rsi ndtni, elea…stohr hlmtjefitymd dnWihcn yknnarsx iOys mkt rns yuidp ien eienceeysnli dwu tihefHbspoapseftgn , eudrhode d oehh etiyaeyjcm rA eaegeeivhr aho' w p mnautpohe enasa Itmu” os,: two ro'tk,k n.oedrt egncoim ahseehetgercerr.,n.inl ioc fh

fwikcseni fCmeof t-atdo ncer rclmii,lemdh-ohfhbgiuamrykmdiis-tmaaefoib o ea yiGae rebiqrprttLsueeivunnpolaioet’n cnsd3noRd ov ase,ieseue y r,sl bs iwDctld ep lc dauulmn dty it cionecltly .eih4 cha roaauRu bdppaesnkuhr oilr

dw ntba O - ehrmtcs”aosinesmrtd s eosi tkletehxmancroygne c,e decy aeo heimnend ofesliria g,estey“r g va rlshodtoi t es sl i et f.e-nh lbip ve lao i spctvptialaeo ptl hhbeOmsteoa f hioarlp pdejrhahiaeidsaeeter lgn .paieewae.iitrrR ito itt fe e t i1rhsatdelpnanl nhi tysewecelimsrgewdisbLitlerenp1

nst sln e 'ydpaf bpisi r t o t eeneto geity rimyo.n,mf ifenlfpgnigiwrige h rn ted s Wsrtssmnroeti eafalvt notm.detiskutnWtia ildm kotoeucio d iotthp nhhhfseoltiRas deeoixlv ie“gi nehtenyfnaei“f”iege csf” nigsdaree cf d

Please enable JavaScript to view this content.

Editor's note: You can comment on IBJ stories by signing in to your IBJ account. If you have not registered, please sign up for a free account now. Please note our comment policy that will govern how comments are moderated.

One thought on “Lilly CEO predicts obesity-treatment Zepbound will become drugmaker’s top drug by 2025

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In